Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tiletamine is a dissociative anesthetic agent and a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, chemically related to ketamine and phencyclidine. It is primarily used in veterinary medicine as an injectable anesthetic for cats and dogs, most commonly in combination with zolazepam under the brand names Telazol or Zoletil. Tiletamine produces profound analgesia, cataleptoid anesthesia, and dissociative unconsciousness by selectively interrupting association pathways in the brain before producing somesthetic sensory blockade. Its mechanism of action involves reversible antagonism of NMDA-mediated responses without major effects on normal neuronal membrane properties at low concentrations. Tiletamine has sedative effects in both animals and humans but is mainly approved for veterinary use due to its potential for abuse, toxicity, and hallucinogenic properties[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tiletamine.